Cargando…
Development of an Integrated Subspecialist Multidisciplinary Neuro-oncology Service
Traditionally, the poor outcome for patients with malignant brain tumours led to therapeutic nihilism. In turn, this resulted in lack of interest in neurosurgical oncology subspecialisation, and less than ideal patient pathways. One problem of concern was the low rate of tumour resection. Between 19...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
British Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652738/ https://www.ncbi.nlm.nih.gov/pubmed/26734207 http://dx.doi.org/10.1136/bmjquality.u201857.w981 |
_version_ | 1782401810060804096 |
---|---|
author | Price, Stephen J Guilfoyle, Mathew J Jefferies, Sarah Harris, Fiona Oberg, Ingela G Burnet, Neil Santarius, Thomas Watts, Colin |
author_facet | Price, Stephen J Guilfoyle, Mathew J Jefferies, Sarah Harris, Fiona Oberg, Ingela G Burnet, Neil Santarius, Thomas Watts, Colin |
author_sort | Price, Stephen J |
collection | PubMed |
description | Traditionally, the poor outcome for patients with malignant brain tumours led to therapeutic nihilism. In turn, this resulted in lack of interest in neurosurgical oncology subspecialisation, and less than ideal patient pathways. One problem of concern was the low rate of tumour resection. Between 1997 and 2006, 685 treated glioblastomas were identified. In the first four years only 40% of patients underwent tumour resection, rising to 55% in the last four years. Before revision of the pathway, the median length of hospital stay was 8 days, and 35% of patients received the results of their histology outside of a clinic setting. A pathway of care was established, in which all patients were discussed pre-operatively in an MDT meeting and then directed into a new surgical neuro-oncology clinic providing first point of contact. This limited the number of surgeons operating on adult glioma patients and aided recruitment into research studies. Now, three consultant neurosurgeons run this service, easily fulfilling IOG requirement to spend >50% of programmed activities in neuro-oncology. Nursing support has been critical to provide an integrated service. This model has allowed increased recruitment to clinical trials. The introduction of this service led to an increase in patients discussed pre-operatively in an MDT (66% rising to 87%; P=0.027), an increase in the rate of surgical resection (from 40% to 80%) and more patients being admitted electively (from 25% to 80%; P<0.001). There was a reduction in the median length of stay (8 days reduced to 4.5 days; P<0.001). For the cohort of GBM patients that went on to have chemoradiotherapy we improved median survival to 18 months, with 35% of patients alive at two years, comparable to international outcomes. Implementing a specialist neurosurgical oncology service begins with understanding the patient care pathway. Our patients have benefitted from the culture of subspecialisation and the excellent inter-disciplinary working relationships that have been developed. |
format | Online Article Text |
id | pubmed-4652738 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | British Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-46527382016-01-05 Development of an Integrated Subspecialist Multidisciplinary Neuro-oncology Service Price, Stephen J Guilfoyle, Mathew J Jefferies, Sarah Harris, Fiona Oberg, Ingela G Burnet, Neil Santarius, Thomas Watts, Colin BMJ Qual Improv Rep BMJ Quality Improvement Programme Traditionally, the poor outcome for patients with malignant brain tumours led to therapeutic nihilism. In turn, this resulted in lack of interest in neurosurgical oncology subspecialisation, and less than ideal patient pathways. One problem of concern was the low rate of tumour resection. Between 1997 and 2006, 685 treated glioblastomas were identified. In the first four years only 40% of patients underwent tumour resection, rising to 55% in the last four years. Before revision of the pathway, the median length of hospital stay was 8 days, and 35% of patients received the results of their histology outside of a clinic setting. A pathway of care was established, in which all patients were discussed pre-operatively in an MDT meeting and then directed into a new surgical neuro-oncology clinic providing first point of contact. This limited the number of surgeons operating on adult glioma patients and aided recruitment into research studies. Now, three consultant neurosurgeons run this service, easily fulfilling IOG requirement to spend >50% of programmed activities in neuro-oncology. Nursing support has been critical to provide an integrated service. This model has allowed increased recruitment to clinical trials. The introduction of this service led to an increase in patients discussed pre-operatively in an MDT (66% rising to 87%; P=0.027), an increase in the rate of surgical resection (from 40% to 80%) and more patients being admitted electively (from 25% to 80%; P<0.001). There was a reduction in the median length of stay (8 days reduced to 4.5 days; P<0.001). For the cohort of GBM patients that went on to have chemoradiotherapy we improved median survival to 18 months, with 35% of patients alive at two years, comparable to international outcomes. Implementing a specialist neurosurgical oncology service begins with understanding the patient care pathway. Our patients have benefitted from the culture of subspecialisation and the excellent inter-disciplinary working relationships that have been developed. British Publishing Group 2013-08-21 /pmc/articles/PMC4652738/ /pubmed/26734207 http://dx.doi.org/10.1136/bmjquality.u201857.w981 Text en © 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ http://creativecommons.org/licenses/by-nc/2.0/legalcode |
spellingShingle | BMJ Quality Improvement Programme Price, Stephen J Guilfoyle, Mathew J Jefferies, Sarah Harris, Fiona Oberg, Ingela G Burnet, Neil Santarius, Thomas Watts, Colin Development of an Integrated Subspecialist Multidisciplinary Neuro-oncology Service |
title | Development of an Integrated Subspecialist Multidisciplinary Neuro-oncology Service |
title_full | Development of an Integrated Subspecialist Multidisciplinary Neuro-oncology Service |
title_fullStr | Development of an Integrated Subspecialist Multidisciplinary Neuro-oncology Service |
title_full_unstemmed | Development of an Integrated Subspecialist Multidisciplinary Neuro-oncology Service |
title_short | Development of an Integrated Subspecialist Multidisciplinary Neuro-oncology Service |
title_sort | development of an integrated subspecialist multidisciplinary neuro-oncology service |
topic | BMJ Quality Improvement Programme |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652738/ https://www.ncbi.nlm.nih.gov/pubmed/26734207 http://dx.doi.org/10.1136/bmjquality.u201857.w981 |
work_keys_str_mv | AT pricestephenj developmentofanintegratedsubspecialistmultidisciplinaryneurooncologyservice AT guilfoylemathew developmentofanintegratedsubspecialistmultidisciplinaryneurooncologyservice AT jjefferiessarah developmentofanintegratedsubspecialistmultidisciplinaryneurooncologyservice AT harrisfiona developmentofanintegratedsubspecialistmultidisciplinaryneurooncologyservice AT obergingela developmentofanintegratedsubspecialistmultidisciplinaryneurooncologyservice AT gburnetneil developmentofanintegratedsubspecialistmultidisciplinaryneurooncologyservice AT santariusthomas developmentofanintegratedsubspecialistmultidisciplinaryneurooncologyservice AT wattscolin developmentofanintegratedsubspecialistmultidisciplinaryneurooncologyservice |